Product Hopping in the Drug Industry — Lessons from Albuterol
Olivier J. Wouters, William B. Feldman, S. Sean Tu
Abstract
Product hops to albuterol inhalers containing hydrofluoroalkane rather than chlorofluorocarbons cost payers and patients billions of dollars. Without patent and regulatory reform, this pattern is likely to be repeated.
Topics & Concepts
MedicineProduct (mathematics)DrugDrug industrySalbutamolMarketingPharmacologyIntensive care medicineAnesthesiaAsthmaBusinessInternal medicineBiotechnologyGeometryBiologyMathematicsInhalation and Respiratory Drug DeliveryPharmaceutical studies and practicesAsthma and respiratory diseases